Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
Tentang
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Muenchen, saham Satsuma Pharmaceuticals diperdagangkan dengan simbol 1LV.MU.
Apakah Satsuma Pharmaceuticals membayar dividen?▼
Ya, dividen 1LV.MU dibayarkan triwulanan. Dividen terakhir per saham adalah 0,14 . Per hari ini, Dividend Yield (FWD)% adalah 0%.
Berapa jumlah karyawan Satsuma Pharmaceuticals?▼
Per 2 November 2026, perusahaan memiliki 25 karyawan.
Satsuma Pharmaceuticals berada di sektor apa?▼
Satsuma Pharmaceuticals beroperasi di sektor Manufaktur.